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Abstract 
 
Background: Although palliative chemotherapy is the standard of care for 
patients diagnosed with stage IV NSCLC, patients with a small metastatic 
burden, “oligometastatic” disease, may benefit from definitive local therapy.  
Methods: We identified 186 patients (26% of Stage IV patients) prospectively 
enrolled in our institutional database from 2002-2012 with oligometastatic 
disease, which we defined as five or fewer distant metastatic lesions at 
diagnosis. Univariable and multivariable Cox proportional hazards models were 
used to identify patient and disease factors associated with improved survival. 
Using propensity score methods, we investigated the effect of definitive local 
therapy to the primary site on overall survival.  
Results: Median age at diagnosis was 61 years, 51% of patients were female, 
12% had squamous histology, and 33% had N0-1 disease. On multivariable 
analysis, ECOG performance status ≥2 (hazard ratio [HR] 2.43), nodal status N2-
3 (HR 2.16), squamous pathology, and metastases to multiple organs (HR 2.11) 
were associated with a greater hazard of death (all p<0.01). Number of 
metastatic lesions and size of primary were not significantly associated with 
overall survival. Definitive local therapy to the primary tumor was associated with 
prolonged survival (HR 0.65, p=0.043).  
Conclusions: Definitive local therapy to the primary tumor appears to be 
associated with improved survival in patients with oligometastatic NSCLC. Select 
patient and tumor characteristics, including good performance status, non-! 3!
squamous histology, and limited nodal disease, may predict for improved survival 
in these patients. !   
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Glossary Listing Abbreviations 
 
 
AJCC – American Joint Committee on Cancer 
BED – Biologically equivalent dose 
CI – Confidence interval 
Cm(s) – Centimeter(s) 
CT – Computed tomography 
ECOG – Eastern Cooperative Oncology Group 
EGFR – Epidermal growth factor receptor 
HR – Hazard ratio 
Kg(s) – Kilogram(s) 
Mo(s) - Month(s) 
MRI – Magnetic resonance imaging 
NSCLC – Non-small cell lung cancer 
OR – Odds ratio 
PET – Positron emission tomography 
SBRT – Stereotactic body radiation therapy 
SEER – Surveillance, Epidemiology, and End Results program 
WBRT – Whole brain radiation therapy! 6!
 
Introduction 
 
Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the 
United States, accounting for approximately 140,000 deaths in 2011.
1 Nearly 
40% of patients present with metastatic disease, with median survival 8-10 
months even with treatment.
2 
 
Palliative chemotherapy is considered the standard of care for patients 
presenting with stage IV non-small cell lung cancer (NSCLC).
2, 3 Of lung and 
bronchus cancer cases diagnosed from 1996-2004, nearly half were diagnosed 
after the cancer had already metastasized, termed stage 4 disease.  
 
 
However, patients with limited metastatic burden – “oligometastatic” disease – 
may have a better prognosis. For example, one Southwest Oncology Group 
review including 2531 patients showed that a single metastatic lesion 
corresponded to an average 1 to 3 month greater survival than multiple 
metastatic lesions.
4 Some series have shown long-term survivors among those 
with oligometastatic disease, and therefore many centers may opt to manage this 
subset of patients with definitive treatment to the primary tumor with the small 
hope of achieving cure. Furthermore, while older studies have reported that only 
a small subset (~7%) of patients present with a solitary site of metastatic 
disease
3, this number in the era of PET-screening is largely unknown. 
 ! 7!
The definition of oligometastatic disease can vary and has ranged in studies from 
the presence of a single metastatic lesion to a single organ with multiple 
metastases to multiple lesions in multiple organs.
5-7 These definitions can limit 
the number of participants involved in a study. For example, one single-institution 
series from a database of 1509 patients with metastatic NSCLC who underwent 
surgery to the primary identified only ten patients with a synchronous solitary 
hematogenous metastasis, defined as a metastasis present upon diagnosis of 
the primary tumor.
5 Staging workup consisted of a comprehensive body CT scan, 
magnetic resonance imaging (MRI) in the case of suspected brain metastases, 
and total body positron emission tomography (PET) scan. In contrast, another 
retrospective study from a database of 169 patients who underwent diagnostic or 
therapeutic surgical procedures for metastatic lung cancer identified 29 patients 
with a single organ of metastatic disease.
6 The definition of oligometastatic 
disease in many of these studies has been derived tautologically from patients 
treated aggressively. Thus, an objective criteria for oligometastatic disease is 
lacking.  
 
!
However, recent series have allowed patients with up to five discrete metastatic 
lesions total to be included in the definition of oligometastatic disease.
8-10 Though 
several studies have reported favorable outcomes with the use of definitive local 
therapy in oligometastatic NSCLC, many are limited to single-institution studies 
that compare results to historical controls.
7, 8, 11, 12 Select series have found one-
year overall survivals ranging from 65% to 74% for patients with oligometastatic 
disease receiving complete surgical resection of the primary tumor
6, 7, 13, and ! 8!
54% to 62% for patients receiving chemoradiation with curative intent to the 
primary site.
8, 14, 15_ENREF_11 However, these results are likely biased by the 
tumor characteristics of the patients selected. Surgical series have required 
potentially resectable primary disease in the chest and focused on patients with 
primarily brain metastases
6, 16, while chemoradiation studies have included 
patients with primary tumors not considered surgically resectable and metastatic 
sites such as bone that are not ordinarily resected.
8, 15 
 
Small case series have shown that for individuals with favorable risk factors, for 
example good performance status and limited weight loss, aggressive therapy – 
including surgery, chemotherapy, and/or radiation – to the primary tumor may 
result in prolonged survival.
7, 17-19 One large retrospective study of 78 patients 
with five or fewer metastatic lesions who were treated with chemoradiation 
therapy showed increased overall survival and reduced tumor burden in patients 
who received high-dose primary radiotherapy and received definitive local 
metastatic treatment compared to historical controls.
8 Another study of 29 
patients with a single organ with metastatic disease treated with surgery to the 
primary site demonstrated median survival of 20.5 months, with one- and five- 
year survivals of 65% and 36%, respectively.
6 Finally, a surgical series of 53 
patients with oligometastatic NSCLC who were treated with curative surgery 
demonstrated median overall survival of 19 months, with one- and five-year 
survivals of 73% and 24%, respectively.
20 While these survival rates all compare 
favorably to historical controls, it is again important to note that these series 
involved highly selected individuals and lacked a control group. Thus, it is difficult ! 9!
to draw definitive conclusions about the benefit of definitive therapy from these 
studies.  
 
Other favorable mediators of survival in NSCLC exist as well.
2 Survival may 
further depend on patient and tumor characteristics, such as metastatic site: for 
example, retrospective reviews suggest that median survival even with 
aggressive treatment may differ between solitary synchronous brain (7-24 
mos)
13, 21, 22 and adrenal (11-31 mos)
23, 24 metastases. For example, five-year 
survival rates in NSCLC based on data from 13 SEER sites are greater for 
females vs. males (20.0% vs. 14.8%), whites vs. blacks (17.8% vs. 14.5%), and 
age < 65 vs. age > 65 (20.2% vs. 15.6%). Overall, this suggests that even within 
oligometastatic disease, survival likely depends heavily on other demographic 
factors and tumor characteristics.  
 
While these series suggest that patients with oligometastatic disease may have 
prolonged survival with definitive surgery or chemoradiation, there have been no 
randomized comparisons of definitive versus palliative management of these 
patients. Furthermore, nearly all of these retrospective series have included 
highly selected groups of patients who had favorable risk factors, for example 
good performance status and limited weight loss, who might also be expected to 
do relatively well with palliative therapies. Therefore, it is not clear whether 
patient outcomes would have differed significantly if these patients had been 
managed with only palliative measures upfront. Moreover, aggressive therapies 
in patients with “incurable” cancers can be associated with emotional, financial, ! 10!
and quality-of life costs in the face of uncertain benefits.
25, 26 This is important 
because all retrospective studies of patients with oligometastatic NSCLC have 
focused on survival as the primary outcome. No comparative effectiveness study 
on treatment for oligometastatic NSCLC exists that factors quality of life after 
treatment. Thus, studies that suggest the benefit of definitive therapy may not 
capture the full consequence of therapy.  
 
In the absence of randomized data, retrospective comparisons of patients 
presenting with oligometastatic NSCLC managed with or without definitive local 
therapy can provide additional information regarding which patients may benefit 
most from definitive treatment to the primary tumor. Furthermore, such evidence 
comparing patients managed with or without definitive local therapy would 
provide important insight into the argument for aggressive local therapy in 
oligometastatic NSCLC and may address the significant selection bias that exists 
in previous retrospective analyses. The purpose of this retrospective cohort 
analysis is to compare survival outcomes in patients with oligometastatic NSCLC 
who receive definitive local therapy to the primary tumor vs. patients with 
oligometastatic NSCLC who do not receive definitive local therapy. Using a 
cohort of patients diagnosed with metastatic NSCLC presenting to the Thoracic 
Oncology Program at the Dana-Farber Cancer Institute from 2002 to 2012 with a 
minimum of one year of follow-up, we identified patients who presented with 
oligometastatic disease at diagnosis and compared survival outcomes among 
patients who received and did not receive definitive local therapies. We ! 11!
furthermore identified patient and disease factors that were associated with 
prolonged survival among patients with oligometastatic NSCLC.  ! 12!
 
Methods 
 
Study cohort 
 
We identified patients presenting with stage IV NSCLC (AJCC 7
th edition) who 
consented and were prospectively enrolled in our institutional database from 
2002 to 2012 within 12 months after diagnosis. Inclusion criteria included stage 
IV disease at diagnosis, sufficient radiologic and/or pathologic records at 
presentation to determine tumor stage, sufficient follow-up records to determine 
treatment, no prior radiation therapy, and no history of prior malignancy other 
than successfully treated skin cancer. All patients provided written informed 
consent and the investigation was approved by the Dana-Farber/Harvard Cancer 
Center Institutional Review Board.  
 
Identification of oligometastatic disease 
 
We defined oligometastatic disease as five or fewer total discrete distant 
metastatic lesions involving any organ system visualized on PET-CT and/or MRI 
of the brain at the time of initial staging. Recent series have identified patients 
with this definition of oligometastatic disease as potentially eligible for high-dose 
radiation to the primary site of cancer.
8, 9_ENREF_12  
 
 
Definition of key variables ! 13!
 
The primary outcome variable was overall survival, which was defined as the 
time from date of pathological diagnosis to date of death or last follow-up.
27, 28 
 
Key covariates included patient, disease, and treatment characteristics. Patient 
characteristics included age in years (<65, ≥65), gender (male, female), race 
(white, non-white), ECOG performance status (0-1, 2+), weight loss in the six 
months prior to diagnosis (≤10%, >10%) and smoking history (never/former, 
current smoker). Smoking information was prospectively collected by self-report. 
A never smoker was defined as a person who smoked fewer than 100 cigarettes 
in their lifetime and a former smoker was defined as a person who had quit one 
year or longer before their diagnosis. Disease characteristics included tumor size 
(≤3 cm, >3cm), nodal spread of disease (N0-1, N2-3), organ sites with metastatic 
involvement (brain, bone, adrenal, other single site, multiple sites), pathology 
(non-squamous epidermal growth factor receptor (EGFR) wild type or unknown, 
non-squamous EGFR activating mutation, squamous) and number of metastatic 
lesions (1, 2, 3-5). Treatment characteristics examined included use of 
aggressive local therapy to primary and metastatic sites. We defined aggressive 
local therapy of primary disease as either surgical resection and/or definitive 
radiation of biological equivalent dose (BED10 without time adjustment) ≥53 or 
stereotactic body radiation therapy (SBRT) to the primary tumor. We defined 
aggressive local therapy of metastatic disease as surgical resection and/or 
definitive radiation (BED ≥53, whole brain radiation therapy [WBRT], stereotactic 
radiosurgery [SRS], or SBRT) to all known sites of metastatic disease.  ! 14!
 
Statistical methods 
 
Overall survival among patients diagnosed with oligometastatic versus more 
extensive disease was compared using univariable Cox proportional hazards 
regression. Because our institutional database only began to enroll all patients 
with lung cancer diagnoses starting in 2009 (prior to this date, most patients were 
selectively enrolled for specific projects based on likely genomic characteristics), 
survival comparisons between these cohorts were made only for those 
diagnosed in 2009 and after.  
 
Among patients diagnosed with oligometastatic disease from 2002-2012, 
univariable and multivariable Cox proportional hazards models with backward 
selection were used to analyze patient and disease factors associated with 
overall survival. Univariable associations between patient and disease factors 
with receipt of definitive local therapy were assessed using Fisher's exact test. To 
evaluate the association between definitive local therapy and overall survival, 
propensity score analyses were performed using inverse probability weights to 
balance measurable confounders between those who did and did not receive 
definitive treatment; all variables described in Table 1 were used to calculate the 
patient's propensity to receive definitive treatment, regardless of statistical 
significance.
29, 30  
 ! 15!
P values were two-sided and values <0.05 were considered statistically 
significant. Patients with missing values for any of the key covariates were 
excluded from analyses that used those specific variables. All analyses were 
performed using Stata (version 11.2) software (Stata Corp LP, College Station, 
Texas). 
 ! 16!
 
Results 
 
We identified 725 patients diagnosed with NSCLC who satisfied our inclusion 
criteria. Of these, 186 patients (26%) had oligometastatic disease at diagnosis 
and 539 patients (74%) had more extensive disease. Figure 1 summarizes our 
study cohort.  
 
Overall survival among patients with oligometastatic versus more extensive 
disease 
 
Among 423 patients diagnosed with metastatic lung cancer between 2009-2012, 
19% had oligometastatic disease, which we defined as five or fewer discrete 
lesions. Median survival was 17 months versus 14 months for patients with 
versus without oligometastatic disease (hazard ratio 0.73, 95% CI 0.53-1.01, 
p=0.054, see Figure 2). 
 
Factors associated with survival for patients with oligometastatic NSCLC 
 
Among 186 patients diagnosed with oligometastatic lung cancer between 2002-
2012, there were 140 deaths. The median follow-up for survivors was 24 months. 
Median age at diagnosis was 61 years, 51% of patients were female, 12% had 
squamous histology, and 33% had N0-1 disease. 38% had brain metastases, 
41% had bone metastases, and 80% had a single organ involved with one or ! 17!
more metastases. 52% had a single metastatic lesion in a single metastatic site. 
Baseline patient characteristics are summarized in Table 1. 
 
Overall, 9% of patients received aggressive treatment to the primary tumor 
only, 17% to metastatic sites only, 20% to both primary and metastatic sites, and 
54% to neither site. Preliminary unadjusted analyses indicated that patients who 
received aggressive local treatment to either the primary tumor only (HR 0.64, 
95% CI 0.33-1.24, p=0.189) or to both primary tumor and metastatic sites (HR 
0.59, 95% CI 0.37-0.95, p=0.029) had improved survival compared to patients 
who received either aggressive treatment to the metastatic sites only or no 
aggressive treatment (see Table 2). Therefore, definitive primary treatment was 
defined as aggressive treatment to the primary tumor with or without aggressive 
treatment to the metastatic sites. Patients with fewer metastatic lesions and lower 
nodal stage were significantly more likely to receive definitive treatment. Site of 
metastasis was also associated with receipt of definitive treatment (in reference 
to brain-only metastases: odds ratio [OR] 0.15 for bone-only metastases, OR 
0.34 for adrenal-only metastases, OR 0.34 for other single-site metastases, and 
OR 0.10 for multiple sites of metastases; global p<0.001); 54% of patients with 
brain-only metastases received definitive treatment, while 15% with bone-only 
metastases and 11% with metastases in multiple organs received definitive 
primary therapy.  
 
Table 3 contains results of univariable and multivariable analyses to determine 
associations between clinicopathologic characteristics and overall survival. On ! 18!
multivariable analysis, ECOG performance status ≥2 vs <2 (HR 2.43, 95% CI 
1.39-4.25, p=0.002), nodal status N2-3 vs N0-1 (HR 2.16, 95% CI 1.43-3.28, 
p<0.001), pathology (in reference to non-squamous EGFR wild-type: HR 1.97 
[95% CI 1.14-3.40] for squamous, and HR 0.46 [95% CI 0.25-0.85] for non-
squamous EGFR activating; overall p=0.001), and having more than one 
metastatic organ involved (HR 2.11, 95% CI 1.36-3.26, p=0.001) were 
significantly associated with overall survival. As shown in Table 4, site of 
metastatic disease was not associated with overall survival after controlling for 
number of metastatic organs, as all hazard ratio confidence intervals were 
overlapping.  
 
Propensity score analysis of definitive versus nondefinitive primary treatment 
 
The median overall survival was 19 months (95% CI 13 to 34 months) for 
patients who received definitive primary treatment versus 16 months (95% CI 13 
to 19 months) for patients who did not receive definitive treatment. The 
unadjusted hazard ratio for death associated with definitive treatment was 0.62 
(95% CI 0.42 to 0.93, p=0.019). After propensity score adjustment with inverse 
probability weights, the adjusted hazard ratio associated with definitive treatment 
was 0.65 (95% CI 0.43 to 0.99, p=0.043). Additional analyses using alternative 
propensity score methodologies confirmed the favorable survival for patients 
receiving definitive treatment, with adjusted hazard ratios ranging from 0.68 to 
0.73. As shown in Table 5, propensity score matching removed significant 
demographic risk factor differences between patients receiving definitive versus ! 19!
non-definitive therapy. Thus, we can be reasonably confident in the results of our 
head-to-head comparison of overall survival between patients receiving and not 
receiving definitive therapy.    
 ! 20!
 
Discussion, Conclusions, and Suggestions for Future Work 
 
Discussion and Conclusions 
 
Stage IV NSCLC is associated with low survival; however, patients diagnosed 
with oligometastatic disease may have a better prognosis than those with more 
extensive disease. Several small case series have suggested improved 
outcomes with definitive treatment to the primary tumor in oligometastatic 
disease.
7, 11, 17, 18 Our study provides further comparative evidence of a survival 
benefit of definitive therapy to the primary tumor in patients with oligometastatic 
disease, using a control group of patients with oligometastatic disease who did 
not receive definitive primary therapy. !
 
Patients in our cohort with oligometastatic NSCLC at diagnosis had greater 
overall survival compared to those with more extensive stage IV disease (median 
17 months versus 14 months). This three-month survival difference is similar to 
what has been reported in a previous analysis of Southwest Oncology Group 
trials, which showed a 3.6-month and 20% one-year survival improvement in 
patients with a single metastatic lesion compared to those with multiple 
metastatic lesions.
4  
 
Among patients with oligometastatic disease, defined as five or fewer lesions, we 
identified several factors associated with improved survival, including better 
performance status, lower nodal stage, non-squamous pathology
 , and fewer ! 21!
metastatic organs involved. Many of these factors have been described in the 
literature as positive prognostic factors in oligometastatic NSCLC.
 8, 13, 31 
Interestingly, low number of metastatic lesions and small radiologic size of the 
primary tumor, which have been associated with favorable progression-free 
survival in other case series, were not significantly associated with longer overall 
survival in our cohort.
8, 9, 32 Fewer discrete metastatic lesions in patients with 
oligometastatic NSCLC has been associated with improved progression-free 
survival in other retrospective case series
9, 32,
 as has tumor volume.
8 The 
discrepancy in findings between these studies and ours is likely explained by the 
fact that previous studies have included only patients with metastases amenable 
to definitive treatment, whereas our study looked at all patients with 
oligometastatic disease, regardless of treatment received. 
 
Previous large case series have evaluated the use of definitive local treatment to 
the primary tumor in oligometastatic disease. In particular, one large 
retrospective study of 78 patients with less than five metastatic lesions who were 
treated with high-dose radiotherapy to the primary tumor showed one- and three-
year overall survival rates of 62% and 25%, respectively.
8 Another two-institution 
study of 61 patients with one to three synchronous metastatic lesions treated with 
surgical resection and/or definitive radiation to all sites of disease showed one- 
and two-year overall survival of 54% and 38%, respectively.
14 One prospective 
phase II trial of 40 patients with less than five metastatic lesions demonstrated 
one-, two-, and three- year overall survival rates of 56%, 23%, and 18%, 
respectively.
15 Although these studies suggest that favorable outcomes can be ! 22!
achieved with definitive local therapy, they lacked a comparator group of patients 
with oligometastatic disease who were not definitively managed. Thus, the 
external validity of these studies remains in question. 
 
Propensity score adjustment provides a useful way to account for relevant 
covariates and to control for possible selection bias due to observed confounders 
between patients who received definitive versus palliative therapy. In essence, 
propensity score matching attempts to reduce bias due to confounding in 
observational studies by attempting to mimic randomization. Propensity matching 
achieves this by creating a sample in the experimental group that is comparable 
on all observed covariates to the control group.  
 
A key advantage of propensity score matching is that it attempts to control for a 
number of covariates between the control and experimental group (see Table 5). 
Our propensity score analyses suggested that definitive treatment of patients 
with oligometastatic NSCLC conferred a survival benefit to patients with 
oligometastatic NSCLC. Site of oligometastatic disease (e.g. brain, bone, 
adrenal) was not independently associated with overall survival, although 
patients with brain-only metastases were more likely to receive definitive therapy.  
 
There are several limitations to this study. No retrospective analysis can replace 
a properly conducted randomized trial. Therefore these results should be 
interpreted with caution. Although we adjusted for propensity to receive definitive 
local therapy based on observed patient characteristics, propensity scores ! 23!
cannot adjust for unobserved characteristics. It is possible that patients receiving 
definitive local therapy were more likely to have additional favorable 
characteristics that we could not control for. In the absence of a randomized 
study, however, retrospective analyses can inform clinical decision-making and 
provide the basis for future randomized comparisons. 
 
Additionally, while our single-institution database began enrolling some patients 
in 2002, the database did not enroll all patients with lung cancer diagnoses until 
2009. Therefore, data for patients enrolled between 2002 and 2009 may have 
selection bias. We attempted to control for this by only conducting survival 
comparisons in cohorts diagnosed after 2009. We additionally addressed 
confounding through propensity score adjustments.  
 
The median survival of non-oligometastatic patients in our study (14 months) is 
higher than that reported in historical controls.
2 This is likely due to the patient 
cohort seen at our institution, which tends to be younger and with a higher 
proportion of white, female, and non-smoking patients than the general 
population of patients diagnosed with lung cancer.
2, 33  
 
Finally, our study was not powered to assess different methods of definitive 
treatment and thus could not compare the effects of surgery versus radiation to 
the primary tumor. This study was also not powered to detect the mediating 
effects of patient and tumor characteristics on the efficacy of definitive treatment. 
Overall survival may depend on patient and tumor characteristics such as ! 24!
metastatic site: for example, retrospective reviews suggest that median survival 
even with definitive treatment may differ between solitary synchronous brain (7-
24 mos)
13, 21, 22_ENREF_20 and adrenal (11-31 mos)
23, 24 metastases. 
 
Future Directions 
 
The results of this retrospective cohort study should be further assessed with a 
prospective randomized trial to assess the benefit of definitive treatment in 
oligometastatic NSCLC. A randomized trial is the goal standard for effectiveness; 
however, this may be difficult to perform in this population, as treatment choice is 
highly influenced by patient and physician preference. Nevertheless, there is 
precedent for a randomized trial comparing primarily supportive therapy vs. 
primarily aggressive therapy (e.g. chemotherapy) in stage IV NSCLC.
34 
Furthermore, a randomized trial would address the likely unmeasured variables 
that are potentially biasing the results in this study.   
 
Additional analyses should investigate the role of different definitive therapies for 
oligometastatic disease. Our study was underpowered to compare surgery 
versus radiation for aggressive treatment of metastatic NSCLC. As mentioned 
above, case series in patients with oligometastatic NSCLC who receive definitive 
surgery or radiation to the primary tumor have showed comparable one-year 
survival rates between 50-75%. However, there has never been a prospective 
comparison between the two treatment modalities. Current NCCN guidelines for 
a solitary brain or adrenal metastasis with limited chest-only stage list both ! 25!
surgical resection and stereotactic ablative radiotherapy of the lung lesion as 
potential treatment options.
35 A prospective randomized comparison between 
surgery and radiation for oligometastatic NSCLC would also address the 
significant selection bias that exists in retrospective case series of patients 
treated with primary surgery or radiotherapy, as candidates for surgery are likely 
to have different patient and tumor characteristics compared to candidates for 
radiotherapy.  
 
Additionally, as definitive local therapy may be associated with significant cost 
and quality of life implications, a comparative effectiveness study should be 
performed that takes into account toxicity and utility of the various interventions. 
For example, chest radiotherapy can be associated with short-term (e.g. 
pneumonitis, swallowing difficulties) and long-term effects (e.g. reduction in 
pulmonary function) that could impact quality of life.
36 A comparative 
effectiveness study, such as a decision analysis/Markov model, could take into 
account toxicity rates and utilities that have been reported in prior case studies to 
compare different treatments.
37, 38  
 
Finally, additional observational studies could investigate the role of definitive 
treatment to the primary tumor for oligometastatic recurrence of initially localized 
disease, for which some evidence of efficacy exists. For example, one thirteen-
person study, showed that definitive treatment for oligometastatic recurrence of 
previously resected NSCLC resulted in progression-free survivals of 20 months.
39 
This suggests that definitive local treatment could be a first-line treatment ! 26!
strategy for patients with oligometastatic recurrence of disease. A prospective 
trial comparing patients with oligometastatic NSCLC recurrence who receive 
definitive local therapy versus those who do not is thus certainly necessary.  
 ! 27!
 
Summary 
 
In conclusion, patients with oligometastatic non-small cell lung cancer may have 
improved survival with definitive local therapy; however, prior retrospective 
analyses have based this conclusion on data from historical controls. This study 
suggests that definitive treatment to the primary tumor may confer a survival 
benefit in patients with oligometastatic NSCLC. Furthermore, factors such as 
nodal involvement, pathology, and patient performance status may also influence 
survival and should also be considered in the decision to pursue definitive 
treatment for these patients. This study is limited by its reliance on observational 
data and therefore should be considered hypothesis-generating rather than 
definitive. Future prospective studies should be performed to provide more 
definitive evidence regarding the effect of definitive local therapy in NSCLC.  ! 28!
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Figure Legend 
 
Figure 1. Study cohort.  
Figure 2. Overall survival stratified by presence of oligometastatic disease, 
among patients diagnosed 2009-2012. 
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Figure 2. Overall survival stratified by presence of oligometastatic disease, 
among patients diagnosed 2009-2012. 
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